Microvascular disease: What does the UKPDS tell us about diabetic retinopathy?

Diabetic Medicine

Volumn 25, Issue SUPPL. 2, 2008, Pages 20-24

  Kohner, E M ^a,b  

^a The Medical School   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Blood pressure control; Diabetic retinopathy; Glucose control

Indexed keywords

ATENOLOL; BENFOTIAMINE; CANDESARTAN; CAPTOPRIL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; RUBOXISTAURIN; SULFONYLUREA;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CATARACT EXTRACTION; CLINICAL TRIAL; DIABETIC RETINOPATHY; DISEASE COURSE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; LASER COAGULATION; MEAN ARTERIAL PRESSURE; MICROANEURYSM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOTOGRAPHY; PROLIFERATIVE RETINOPATHY; RETINA MACULA EDEMA; RETINA MACULOPATHY; RETINA VEIN OCCLUSION; REVIEW; RISK REDUCTION; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS HEMORRHAGE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; GREAT BRITAIN; HUMANS; HYPERTENSION; RISK FACTORS; TREATMENT OUTCOME;

EID: 47649091587     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02505.x     Document Type: Review

References (24)

1. Goldberg MF, Fine SL (eds). Symposium on the Treatment of Diabetic Retinopathy. Goldberg MF Fine S (Eds. US Public Health Service, Arlington, VA, USA, 1969.
2. University Group Diabetes Program. A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. Diabetes 1976 25 : 1129 1153.
3. Scott J, Poffenbarger PL. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 1979 28 : 41 51.
4. 1c in diabetes mellitus. N Engl J Med 1976 295 : 417 420.
5. Peterson CM, Jones RL, Dupuis A, Levine BS, Bernstein R, O'Shea M. Feasibility of improved blood glucose control in patients with insulin-dependent diabetes mellitus. Diabetes Care 1979 2 : 329 335.
6. Early Treatment of Diabetic Retinopathy Study Research Group (1991). Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS 12. Ophthalmology 1991 98 : 823 833.
7. UK Prospective Diabetes Study (UKPDS) Group. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 2001 18 : 178 184.
8. Kohner EM, Stratton IM, Aldington SJ, Turner RC, Matthews DR for the UK Prospective Diabetes Study (UKPDS) Group. Microaneurysms in the development of diabetic retinopathy (UKPDS 42). Diabetologia 1999 42 : 1107 1112.
9. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM for the UK Prospective Diabetes Study (UKPDS) Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in Type 2 diabetes mellitus (UKPDS 69). Arch Ophthalmol 2004 122 : 1631 1640.
10. Stratton IM, Matthews DR, Aldington SJ, Holman RR. Risk factors for presence of hard exudates at diagnosis of Type 2 diabetes and after 6 years. Abstract no. 116. Presented at the International Diabetes Federation (IDF) meeting in Paris, France, 24-28 August 2003. Also published in Diabetologia 2003 46 (Suppl 2 A42.
11. Stratton IM, Scanlon PH, Holman RR, Lipinski SL, Aldington SJ. Visual loss related to the position of hard exudates in diabetic maculopathy in Type 2 diabetes in the UKPDS. Presented at the Diabetes UK Meeting, Glasgow, UK, 16-18 March 2007. Also published in Diabetic Medicine 2007 24 (Suppl 1 90.
12. UK Prospective Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
13. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE et al. for the UKPDS Group. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001 44 : 156 163.
14. Stratton IM, Adler AI, Neil HAW, Matthew DR, Manley SE, Cull CA et al. on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000 321 : 405 411.
15. Stevens RJ, Stratton IM, Holman RR. UKPDS 58 : Modeling glucose exposure as a risk factor for photocoagulation in Type 2 diabetes. J Diabetes Complications 2002 16 : 371 376.
16. Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA et al. on behalf of the UK Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000 321 : 412 419.
17. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HAW, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in Type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006 49 : 1761 1769.
18. Nathan DM, Buse JB, Davidson MB, Ferranini E, Holman RR, Sherwin R et al. Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008 31 : 173 175.
19. Chibber R, Ben-Mahmud BM, Chibber S, Kohner EM. Leukocytes in diabetic retinopathy. Curr Diab Rev 2007 3 : 3 14.
20. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe non-proliferative diabetic retinopathy: initial results of the Protein Kinase C β inhibitor Diabetic Retinopathy Study (PKC-DRS). Diabetes 2005 54 : 2188 2197.
21. Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ et al. for the PKC-DRS 2 Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006 113 : 2221 2230.
22. Sjølie AK, Porta M, Parving HH, Bilous R, Klein R : The DIRECT Programme Study Group. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. J Renin Angiotensin Aldosterone Syst 2005 6 : 25 32.
23. Chew EY, Klein ML, Ferris FL 3rd., Remaley NA, Murphy RP, Chantry K et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS report 22). Arch Ophthalmol 1996 114 : 1079 1084.
24. Yamagishi S, Nakamura K, Matsui T, Sato T, Takeuchi M. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy. Med Hypotheses 2006 66 : 1019 1021.